These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 26876462

  • 1. PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes.
    Greco KA, Franzen CA, Foreman KE, Flanigan RC, Kuo PC, Gupta GN.
    Urology; 2016 May; 91():241.e1-7. PubMed ID: 26876462
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact of PLK-1 silencing on endothelial cells and cancer cells of diverse histological origin.
    Gomes CP, Gomes-da-Silva LC, Ramalho JS, de Lima MC, Simões S, Moreira JN.
    Curr Gene Ther; 2013 Jun 01; 13(3):189-201. PubMed ID: 23531193
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro.
    Kawata E, Ashihara E, Nakagawa Y, Kiuchi T, Ogura M, Yao H, Sakai K, Tanaka R, Nagao R, Yokota A, Takeuchi M, Kimura S, Hirai H, Maekawa T.
    Cancer Lett; 2010 Aug 28; 294(2):245-53. PubMed ID: 20206440
    [Abstract] [Full Text] [Related]

  • 8. [PLK1 Expression in Mantle Cell Lymphoma and Its Clinical Significance].
    Shen LY, Lin CM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun 28; 27(3):833-838. PubMed ID: 31204940
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Enhancive effect of PLK1 gene silencing on sensitivity of K562/A02 cells to adriamycin].
    Liu L, Zhang M, Zou P, Tian L, Liu F.
    Ai Zheng; 2006 Apr 28; 25(4):404-8. PubMed ID: 16613670
    [Abstract] [Full Text] [Related]

  • 13. Polo-like kinase 1 is a potential therapeutic target in human melanoma.
    Jalili A, Moser A, Pashenkov M, Wagner C, Pathria G, Borgdorff V, Gschaider M, Stingl G, Ramaswamy S, Wagner SN.
    J Invest Dermatol; 2011 Sep 28; 131(9):1886-95. PubMed ID: 21654832
    [Abstract] [Full Text] [Related]

  • 14. [Influence of silencing Polo-like kinase 1 on migration and invasion of colorectal cancer cells].
    Han DP, Cui JT, Lu AG, Chen XH, Feng B, Zong YP, Qu S, Cao QF, Zheng MH.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2011 Jan 28; 14(1):61-4. PubMed ID: 21271384
    [Abstract] [Full Text] [Related]

  • 15. [Knockdown of PLK1 mRNA by special siRNA].
    Chen GX, Dong QH, Zhang JW, Fu FF, Xu ZF, Liang QY, Zheng S, Ding JY.
    Yi Chuan; 2006 Jan 28; 28(1):21-5. PubMed ID: 16469711
    [Abstract] [Full Text] [Related]

  • 16. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer.
    Kawata E, Ashihara E, Kimura S, Takenaka K, Sato K, Tanaka R, Yokota A, Kamitsuji Y, Takeuchi M, Kuroda J, Tanaka F, Yoshikawa T, Maekawa T.
    Mol Cancer Ther; 2008 Sep 28; 7(9):2904-12. PubMed ID: 18790771
    [Abstract] [Full Text] [Related]

  • 17. [Effect of PLK1 gene silence on cell cycle, proliferation and drug resistance in K562/A02 cells].
    Liu L, Zhang M, Zou P, Tian L, Liu F.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr 28; 14(2):241-6. PubMed ID: 16638189
    [Abstract] [Full Text] [Related]

  • 18. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
    Gomes-da-Silva LC, Ramalho JS, Pedroso de Lima MC, Simões S, Moreira JN.
    Eur J Pharm Biopharm; 2013 Nov 28; 85(3 Pt A):356-64. PubMed ID: 23659854
    [Abstract] [Full Text] [Related]

  • 19. The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity.
    Zhang Y, Liu Y, Yang YX, Xia JH, Zhang HX, Li HB, Yu CZ.
    J Exp Clin Cancer Res; 2009 Sep 23; 28(1):130. PubMed ID: 19775446
    [Abstract] [Full Text] [Related]

  • 20. Polo-like kinase and survivin are esophageal tumor-specific promoters.
    Sato F, Abraham JM, Yin J, Kan T, Ito T, Mori Y, Hamilton JP, Jin Z, Cheng Y, Paun B, Berki AT, Wang S, Shimada Y, Meltzer SJ.
    Biochem Biophys Res Commun; 2006 Apr 07; 342(2):465-71. PubMed ID: 16487489
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.